معرفی
Clyde M. Ofner III, PhD, RPh, is a Professor in the Department of Pharmaceutical Sciences at the Philadelphia College of Pharmacy, University of the Sciences. He joined the institution in 1987 and teaches across multiple programs including Pharmacy, Pharmaceutical Sciences, Pharmacology/Toxicology, Pharmaceutics, and Drug Development and Industrial Pharmacy (DDIP). He holds a BS and PhD from Temple University and is a licensed pharmacist in Pennsylvania.
His research centers on two key themes: (1) Developing macromolecular anti-cancer conjugates (e.g., gelatin-doxorubicin, gelatin-methotrexate) for targeted breast cancer therapy, and (2) Investigating lysosome-mediated cytotoxicity pathways to induce selective cancer cell death. Recent work explores lysosome membrane permeabilization (LMP) mechanisms involving reactive oxygen species and p53 pathways in breast cancer subtypes.
Dr. Ofner's publications primarily focus on drug delivery systems, cancer therapeutics, and biomaterial chemistry, with recent trends emphasizing lysosome-targeted strategies for evading chemotherapy side effects. Earlier work established foundations in gelatin-based conjugates and stability characterization.
Awards & Honors:
- FDA Commissioner’s Special Citation (1995-1998)
- USciences Founders Day Faculty Award of Merit (2016)
- PCP Dean’s Award in Research (2013)
- PCP Dean’s Award in Teaching (2020)
- PCP Dean’s Award in Service (2023)
He has directed over a dozen graduate students and several dozen undergraduates, secured funding from NIH, foundations (national/regional), SJU, PCP, and pharmaceutical companies, and holds international patents for a biodegradable gelatin-doxorubicin conjugate. He advises the Rho Chi honor society and is active in AAPS and AACR.
